var data={"title":"Pramipexole: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pramipexole: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6822?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pramipexole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pramipexole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212309\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mirapex;</li>\n      <li>Mirapex ER</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212310\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT-Pramipexole;</li>\n      <li>Apo-Pramipexole;</li>\n      <li>Auro-Pramipexole;</li>\n      <li>Ava-Pramipexole;</li>\n      <li>Dom-Pramipexole;</li>\n      <li>Mirapex;</li>\n      <li>Mylan-Pramipexole;</li>\n      <li>PMS-Pramipexole;</li>\n      <li>Sandoz-Pramipexole;</li>\n      <li>Teva-Pramipexole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212335\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anti-Parkinson Agent, Dopamine Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212313\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Retitration of dose should be considered for any significant interruption in therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parkinson disease:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> Initial: 0.125 mg 3 times daily, increase gradually every 5 to 7 days; maintenance (usual): 0.5 to 1.5 mg 3 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Discontinuation of therapy: Reduce dose by 0.75 mg per day until daily dose is equivalent to 0.75 mg once daily, then reduce by 0.375 mg per day thereafter</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release:</i> Initial: 0.375 mg once daily; increase gradually not more frequently than every 5 to 7 days to 0.75 mg once daily and then (if necessary) by 0.75 mg per dose; maximum: 4.5 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Discontinuation of therapy: Reduce dose by 0.75 mg per day until daily dose is equivalent to 0.75 mg once daily, then reduce by 0.375 mg per day thereafter.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Converting from immediate release to extended release:</i> May initiate extended-release tablet the morning after the last immediate-release evening tablet is taken. The total daily dose should remain the same.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Restless legs syndrome:</b> Oral: <i>Immediate release:</i> Initial: 0.125 mg once daily 2 to 3 hours before bedtime. Dose may be doubled every 4 to 7 days up to 0.5 mg once daily. Alternatively, a maximum dose of 0.75 mg/day has been recommended (Garcia-Borreguero 2016). <b>Note:</b> If augmentation occurs, dose earlier in the day, divide into multiple daily doses, or consider switching to alternative therapy (Garcia-Borreguero 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Discontinuation of therapy: Worsening of symptoms may occur with abrupt discontinuation; a gradual dose reduction every 4 to 7 days has been recommended (Mirapex Canadian product labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bipolar depression (off-label use):</b> Oral: <i>Immediate release:</i> Initial: 0.125 mg given 2 to 3 times daily; increase gradually by 0.125 to 0.25 mg daily every 3 to 7 days to a target range of 1 to 3 mg/day given in 2 to 3 divided doses. In clinical trials, the average dose was 1.7 mg/day and maximum dose allowed was 4.5 to 5 mg/day. Used in combination with mood stabilizers (Goldberg 2004, Zarate 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fibromyalgia (off-label use):</b> Oral: <i>Immediate release:</i> Initial: 0.25 mg once daily at bedtime; may be increased weekly by 0.25 mg/day increments up to 4.5 mg daily as a single bedtime dose. <b>Note:</b> Study evaluated use in patients receiving concomitant medications (Holman 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212314\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212315\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Parkinson disease: </b>\n      <i>Immediate release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 30 to 50 mL/minute: Initial: 0.125 mg twice daily (maximum: 0.75 mg 3 times daily) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 15 to 29 mL/minute: Initial: 0.125 mg once daily (maximum: 1.5 mg once daily) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;15 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ESRD requiring hemodialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Parkinson disease: </b> <i>Extended release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &gt;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 30 to 50 mL/minute: Initial: 0.375 mg every other day; may increase to 0.375 mg once daily no sooner than 1 week after initiation. If necessary, may increase by 0.375 mg per dose not more frequently than every 7 days; maximum recommended dose: 2.25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;30 mL/minute: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">ESRD requiring hemodialysis: Use not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Restless legs syndrome: </b>\n      <i> Immediate release:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &gt;60 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 20 to 60 mL/minute: No dosage adjustment necessary; however, duration between titration should be increased to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &lt;20 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15028352\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Immediate release and extended release: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, no adjustment expected since undergoes minimal hepatic metabolism.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212288\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as dihydrochloride monohydrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mirapex: 0.125 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mirapex: 0.25 mg, 0.5 mg [scored; contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mirapex: 0.75 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mirapex: 1 mg, 1.5 mg [scored; contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as dihydrochloride monohydrate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mirapex ER: 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg [contains corn starch]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg, 4.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212275\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212291\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Doses should be titrated gradually to avoid the onset of intolerable side effects. The dosage should be increased to achieve a maximum therapeutic effect, balanced against the side effects of dyskinesia, hallucinations, somnolence, and dry mouth. Administer with or without food; administer with food to decrease nausea. Extended-release tablets should be swallowed whole and not chewed, crushed, or divided. For RLS, administer 2 to 3 hours before bedtime; if augmentation occurs, dose earlier in the day, divide into multiple daily doses, or consider switching to alternative therapy (Garcia-Borreguero 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212289\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Parkinson disease:</b> Treatment of Parkinson disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Restless legs syndrome (immediate release only):</b> Treatment of moderate to severe primary restless legs syndrome (RLS).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744699\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bipolar depression; Fibromyalgia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212341\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Mirapex may be confused with Hiprex, Mifeprex, MiraLax</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212282\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Actual frequency may be dependent on dose and/or formulation. All adverse reactions are as reported for Parkinson disease unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Orthostatic hypotension (3% to 53%; dose related)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (Parkinson disease: 9% to 36%; dose related; restless leg syndrome: 6%), extrapyramidal reaction (28%), insomnia (Parkinson disease: 4% to 27%; restless leg syndrome: 13%), dizziness (2% to 26%), hallucination (5% to 17%), headache (restless leg syndrome: 16%; Parkinson disease: 4% to 7%), worsening of restless leg syndrome (augmentation; 12%), abnormal dreams (Parkinson disease: 11%; restless leg syndrome: 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (Parkinson disease: 11% to 28%; dose related; restless leg syndrome: 11% to 27%), constipation (Parkinson disease: 6% to 14%; dose related; restless leg syndrome: 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Dyskinesia (17% to 47%), weakness (3% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (2% to 8%), edema (4% to 5%), chest pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Worsening of restless leg syndrome (rebound; 10%), confusion (4% to 10%), fatigue (restless leg syndrome: 7% to 9%; Parkinson disease: 6%), dystonia (2% to 8%), abnormal gait (7%), hypertonia (7%), amnesia (4% to 6%; dose related), narcolepsy (2% to 6%), falling (4%), impulse control disorder (3% to 4%; eg, binge eating, hypersexuality, pathological gambling, shopping), vertigo (2% to 4%), hypoesthesia (3%), abnormality in thinking (2% to 3%), akathisia (2% to 3%), malaise (2% to 3%), sleep disorder (1% to 3%), equilibrium disturbance (2%), paranoia (2%), depression (2%), delusions (1%), myasthenia (1%), myoclonus (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatological disease (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (2%), decreased libido (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (Parkinson disease: 4% to 7%; restless leg syndrome: 3%), diarrhea (restless leg syndrome: 1% to 7%; Parkinson disease: 2%), anorexia (4% to 5%), vomiting (4%), upper abdominal pain (3% to 4%), dyspepsia (3%), increased appetite (2% to 3%), dysphagia (2%), sialorrhea (2%), abdominal distress (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary frequency (6%), urinary tract infection (4%), impotence (2%), urinary incontinence (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (restless leg syndrome: 3% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Limb pain (restless leg syndrome: 3% to 7%), muscle spasm (5%), arthritis (3%), tremor (3%), back pain (2% to 3%), bursitis (2%), muscle twitching (2%), elevated creatine phosphokinase (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Accommodation disturbance (4%), visual disturbance (3%), diplopia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal congestion (restless leg syndrome: 3% to 6%), dyspnea (4%), cough (3%), rhinitis (3%), pneumonia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Aggressive behavior, agitation, altered mental status, behavioral changes, cardiac failure, delirium, delusions, disorientation, fibrothorax, increased libido, paranoia, retroperitoneal fibrosis, psychotic symptoms, pulmonary fibrosis, rhabdomyolysis, SIADH, syncope, weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212294\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to pramipexole or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212279\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dyskinesias: May cause or exacerbate dyskinesias. Use with caution in patients with preexisting dyskinesias.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Impulse control disorders: Has been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, compulsive buying, libido increases (hypersexuality), binge eating, and/or other intense urges. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Melanoma: Risk for melanoma development is increased in Parkinson disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuroleptic malignant syndrome: Dopaminergic therapy has been reported to cause symptoms resembling neuroleptic malignant syndrome (altered consciousness, autonomic instability, elevated temperature, and muscular rigidity) associated with rapid dose reduction, discontinuation, or changes in therapy; taper dose to decrease risk of hyperpyrexia and confusion.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension; Parkinson disease patients appear to have an impaired capacity to respond to a postural challenge. Use with caution in patients at risk of hypotension (such as those receiving antihypertensive drugs) or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Parkinson patients being treated with dopaminergic agonists ordinarily require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and should be informed of this risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pleural/retroperitoneal fibrosis: Ergot-derived dopamine agonists have been associated with fibrotic complications (eg, retroperitoneal fibrosis, pleural effusion, pleural thickening, pulmonary infiltrates, cardiac valvulopathy). Although pramipexole is not an ergot, there have been postmarketing reports of possible fibrotic complications (peritoneal, pleural, pulmonary) with pramipexole; monitor closely for signs and symptoms of fibrosis. Discontinuation of therapy may resolve complications, but not in all cases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychotic effects: May cause or exacerbate mental status and behavioral changes, which may be severe, including psychotic-like behavior during treatment or after starting or increasing the dose; manifestations may include paranoid ideation, delusions, hallucinations, confusion, psychotic-like behavior, disorientation, aggressive behavior, agitation, and delirium. Avoid use in patients with a major psychotic disorder. Older adults may be at a higher risk for hallucinations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Retinal changes: Pathologic degenerative changes were observed in the retinas of albino rats during studies with this agent, but were not observed in the retinas of albino mice or in other species. The significance of these data for humans remains uncertain.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Somnolence: Patients have reported falling asleep while engaging in activities of daily living; this has been reported to occur without significant warning signs; some of these events had been reported one year after the initiation of therapy. Before initiating treatment, advise patients of the potential to develop drowsiness, and inquire about factors that may increase the risk (eg, concomitant sedating medications and/or alcohol, presence of sleep disorders, concomitant medications that increase pramipexole plasma levels). Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Monitor for daytime somnolence or preexisting sleep disorder; discontinue if significant daytime sleepiness or episodes of falling asleep occur; if a decision is made to continue therapy, advise patients not to drive and to avoid other potentially dangerous activities. Pramipexole has been associated with somnolence.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure (HF): A pooled analysis of randomized, placebo-controlled phase 2 and 3 clinical trials demonstrated a more frequent incidence of newly diagnosed HF (not statistically significant) in patients receiving pramipexole compared with patients receiving placebo (0.28% [12/4,157] vs 0.14% [4/2,820], respectively) (FDA Drug Safety Communication 2012) . Two epidemiologic studies have also suggested an increased incidence of HF. The first epidemiologic study, a case-control study in a United Kingdom cohort of patients receiving anti-Parkinson agents (eg, dopamine agonists), revealed a statistically significant increased risk for HF in patients exposed to any dopamine agonist compared with no exposure (RR: 1.58; 95% CI: 1.26 to 1.96) with pramipexole being associated with a statistically significant increased risk of HF versus no exposure (RR: 1.86; 95% CI: 1.21 to 2.85) (Renoux 2012). In the second epidemiologic study, a case-control study in a cohort of Parkinson disease patients newly initiated on a dopamine agonist or levodopa, found that among the individual non-ergot dopamine agonists studied, only current use of pramipexole was associated with an increased risk of HF compared with levodopa use (OR: 1.61; 95% CI: 1.09 to 2.38). This increased risk occurred in the first 3 months of treatment (OR: 3.06; 95% CI: 1.74 to 5.39) and in patients &ge;80 years of age (OR: 3.30; 95% CI: 1.62 to 7.13). Of note, the increased risk was not significant with pramipexole use &gt;3 months (Mokhles 2012). The FDA has not concluded that pramipexole increases the risk of HF. Due to study limitations and the potential for confounders, the FDA is continuing its review. Monitor for signs and symptoms of heart failure. In a scientific statement from the American Heart Association, pramipexole has been determined to be an agent that may cause direct myocardial toxicity (magnitude: major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dose adjustment may be necessary. Extended-release tablets are not recommended for use in patients with CrCl &lt;30 mL/minute or ESRD requiring hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Restless legs syndrome: Augmentation (earlier onset of symptoms in the evening/afternoon, increase and/or spread of symptoms to other extremities) may occur in some restless leg syndrome (RLS) patients. Risk factors for dopaminergic-induced augmentation include higher doses of dopaminergic agents, use of shorter-acting dopamine agonists (ie, pramipexole, ropinirole) or levodopa, low iron stores, and increased severity of symptoms prior to treatment initiation. To minimize risk of augmentation, treatment should only be initiated when symptoms significantly impact quality of life; intermittent treatment should also be considered. If dopaminergic agents are used as initial treatment, use the lowest effective dose and avoid exceeding recommended doses. If augmentation occurs, dose earlier in the day, divide into multiple daily doses, or consider switching to alternative therapy. End-of-dose rebound (reappearance of symptoms in the early morning hours that are worse than baseline) may also occur (Garcia-Borreguero 2016). Consider dosage adjustment or discontinuation of treatment if rebound symptoms occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: May be prone to an increased risk of adverse drug reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extended-release tablet: Tablet residue resembling a swollen whole or partial tablet may be visible in the stool after taking the extended-release formulation. Some patients reported a worsening of their Parkinson disease symptoms when tablet residue was observed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation of therapy: Taper gradually when discontinuing therapy in patients with Parkinson disease; dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on abrupt withdrawal or significant dosage reduction after long-term use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299931\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212283\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9560&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the sedative effect of Pramipexole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amisulpride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Amisulpride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (First Generation [Typical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Anti-Parkinson Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotic Agents (First Generation [Typical]). Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: Anti-Parkinson Agents (Dopamine Agonist) may enhance the adverse/toxic effect of BuPROPion. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Pramipexole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the sedative effect of Pramipexole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulpiride: May diminish the therapeutic effect of Anti-Parkinson Agents (Dopamine Agonist).<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212306\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food intake does not affect the extent of drug absorption although the time to maximal plasma concentration is delayed when taken with a meal. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212297\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Information related to the use of pramipexole for the treatment of Parkinson disease (Benbir 2013, Mucchiut 2004) or restless legs syndrome (RLS) (Dostal 2013) in pregnant women is limited. Current guidelines note that the available information is insufficient to make a recommendation for the treatment of RLS in pregnant women (Aurora 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212298\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if pramipexole is present in breast milk; however, pramipexole inhibits prolactin secretion in humans and may potentially inhibit lactation. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212299\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken with or without food. May be taken with food to decrease nausea.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212286\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, heart rate (especially during dose escalation); body weight changes; CNS depression, fall risk, behavior changes (eg, compulsive behaviors); periodic skin examinations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212278\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pramipexole is a nonergot dopamine agonist with specificity for the D<sub>2</sub> subfamily dopamine receptor, and has also been shown to bind to D<sub>3</sub> and D<sub>4</sub> receptors. By binding to these receptors, it is thought that pramipexole can stimulate dopamine activity on the nerves of the striatum and substantia nigra.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212293\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 500 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~15%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Negligible (&lt;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Immediate release: &gt;90%; Extended release (as compared to immediate release): 100%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 8.5 hours; Elderly: 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Immediate release: ~2 hours; Extended release: 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (90% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212296\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Mirapex ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.375 mg (7): $154.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75 mg (7): $154.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (7): $154.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.25 mg (30): $664.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (30): $664.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.75 mg (30): $664.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.5 mg (30): $664.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Pramipexole Dihydrochloride ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.375 mg (30): $484.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75 mg (30): $484.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (30): $484.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.25 mg (30): $484.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg (30): $484.13</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.75 mg (30): $532.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4.5 mg (30): $484.13</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Mirapex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg (90): $702.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (90): $702.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (90): $702.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75 mg (90): $702.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (90): $702.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (90): $702.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Pramipexole Dihydrochloride Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.125 mg (90): $277.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg (90): $277.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg (90): $277.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75 mg (90): $265.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg (90): $277.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg (90): $277.55</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212300\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Calmolan (CZ);</li>\n      <li>Ezaprev (LV);</li>\n      <li>Glepark (CZ);</li>\n      <li>Labrixile (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Medopexal (LV);</li>\n      <li>Medopexol (CZ, TR);</li>\n      <li>Miraksol (UA);</li>\n      <li>Miramel (IE);</li>\n      <li>Mirapeks (UA);</li>\n      <li>Mirapex (AR, BB, KR, TW, VE);</li>\n      <li>Mirapex ER (HK);</li>\n      <li>Mirapex-LA (JP);</li>\n      <li>Mirapexin (AT, BE, BG, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HR, HU, IE, IT, LU, LV, MT, NL, PL, PT, RO, RU, SE, SI, TR);</li>\n      <li>Oarmital (PA);</li>\n      <li>Oprimea (UA);</li>\n      <li>Oprymea (ES, GB, IE);</li>\n      <li>Orion (UA);</li>\n      <li>Parmital (CR, DO, GT, HN, NI, SV);</li>\n      <li>Pexola (CO, UY);</li>\n      <li>Pexole (PH);</li>\n      <li>Pramexol (TH);</li>\n      <li>Pramiprex (LK);</li>\n      <li>Pramivex (ID);</li>\n      <li>Prapexin (IE);</li>\n      <li>Ramipex (PH);</li>\n      <li>Sifrol (AE, AR, AT, BE, BG, BH, BR, CH, CL, CN, CY, CZ, DE, DK, EG, FI, FR, GB, GR, HR, ID, IE, IL, IQ, IR, IS, IT, JO, KW, LB, LK, LT, LY, MT, MX, MY, NL, NO, OM, PE, PH, PL, PT, PY, QA, RO, RU, SA, SE, SG, SK, SY, TH, TR, VE, VN, YE);</li>\n      <li>Sifrol ER (CR, CU, DO, GT, HN, KW, LB, MY, NI, PA, PH, SG, SV, TH);</li>\n      <li>Treatson (ID);</li>\n      <li>Xolepral (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aiken CB, &ldquo;Pramipexole In Psychiatry: A Systematic Review Of The Literature,&rdquo; <i>J Clin Psychiatry</i>, 2007, 68(8):1230-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/17854248/pubmed\" target=\"_blank\" id=\"17854248\">17854248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aurora RN, Kristo DA, Bista SR, et al, &quot;The Treatment of Restless Legs Syndrome and Periodic Limb Movement Disorder in Adults-An Update For 2012: Practice Parameters With an Evidence-Based Systematic Review and Meta-Analyses: An American Academy of Sleep Medicine Clinical Practice Guideline,&quot; <i>Sleep</i>, 2012, 35(8):1039-62.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/22851801/pubmed\" target=\"_blank\" id=\"22851801\">22851801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benbir G, Ertan S, and Ozekmekci S, &quot;Successful Pregnancy and Delivery in a Patient With Parkinson's Disease Under Pramipexole Treatment,&quot; <i>Presse Med</i>, 2013, pii: S0755-4982(13)00564-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/23688703/pubmed\" target=\"_blank\" id=\"23688703\">23688703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dostal M, Weber-Schoendorfer C, Sobesky J, et al, &quot;Pregnancy Outcome Following Use of Levodopa, Pramipexole, Ropinirole, and Rotigotine for Restless Legs Syndrome During Pregnancy: A Case Series,&quot; <i>Eur J Neurol</i>, 2013, 20(9):1241-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/23083216/pubmed\" target=\"_blank\" id=\"23083216\">23083216</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA) Drug Safety Communication, &quot;Ongoing Safety Review of Parkinson's Drug Mirapex (pramipexole) and Possible Risk of Heart Failure.&quot; Available at <a href=\"http://www.fda.gov/Drugs/DrugSafety/ucm319779.htm\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm319779.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson's Disease,&rdquo; <i>Neurotherapeutics</i>, 2008, 5(2):164-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/18394561/pubmed\" target=\"_blank\" id=\"18394561\">18394561</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. <i>Sleep Med</i>. 2016;21:1-11. doi: 10.1016/j.sleep.2016.01.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/27448465/pubmed\" target=\"_blank\" id=\"27448465\">27448465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14992985\"></a>Goldberg JF, Burdick KE, and Endick CJ, &ldquo;Preliminary Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole Added to Mood Stabilizers for Treatment-Resistant Bipolar Depression,&rdquo; <i>Am J Psychiatry</i>, 2004, 161(3):564-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/14992985/pubmed\" target=\"_blank\" id=\"14992985\">14992985</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guttman M, &ldquo;Double-Blind Comparison of Pramipexole and Bromocriptine Treatment With Placebo in Advanced Parkinson's Disease,&rdquo; International Pramipexole-Bromocriptine Study Group, <i>Neurology</i>, 1997, 49(4):1060-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16052595\"></a>Holman AJ and Myers RR, &ldquo;A Randomized, Double-Blind, Placebo-Controlled Trial of Pramipexole, a Dopamine Agonist, in Patients With Fibromyalgia Receiving Concomitant Medications,&rdquo; <i>Arthritis Rheum</i>, 2005, 52(8):2495-505.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/16052595/pubmed\" target=\"_blank\" id=\"16052595\">16052595</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberman A, Ranhosky A, and Korts D, &ldquo;Clinical Evaluation of Pramipexole in Advanced Parkinson's Disease: Results of a Double-Blind, Placebo-Controlled, Parallel-Group Study,&rdquo; <i>Neurology</i>, 1997, 49(1):162-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/9222185/pubmed\" target=\"_blank\" id=\"9222185\">9222185</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirapex (pramipexole dihydrochloride) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirapex (pramipexole dihydrochloride) [product monograph]. Burlington, Ontario, Canada: Boehringer Ingelheim (Canada) Ltd: January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirapex ER (pramipexole dihydrochloride) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mokhles MM, Trifir&ograve; G, Dieleman JP, et al, &quot;The Risk of New Onset Heart Failure Associated With Dopamine Agonist Use in Parkinson's Disease,&quot; <i>Pharmacol Res</i>, 2012, 65(3):358-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/22123498/pubmed\" target=\"_blank\" id=\"22123498\">22123498</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molho ES, Factor SA, Weiner WJ, et al, &ldquo;The Use of Pramipexole, a Novel Dopamine (DA) Agonist, in Advanced Parkinson's Disease,&rdquo; <i>J Neural Trans</i>, 1995, 45(Suppl):225-30.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo; <i>Mov Disord</i>, 2000, 15(5):869-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/11009192/pubmed\" target=\"_blank\" id=\"11009192\">11009192</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mucchiut M, Belgrado E, Cutuli D, et al, &quot;Pramipexole-Treated Parkinson's Disease During Pregnancy,&quot; <i>Mov Disord</i>, 2004, 19(9):1114-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/15372610/pubmed\" target=\"_blank\" id=\"15372610\">15372610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Piercey MF, Hoffman WE, Smith MW, et al, &ldquo;Inhibition of Dopamine Neuron Firing by Pramipexole, a Dopamine D(3) Receptor-Preferring Agonist: Comparison to Other Dopamine Receptor Agonists,&rdquo; <i>Eur J Pharmacol</i>, 1996, 312(1):35-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/8891576/pubmed\" target=\"_blank\" id=\"8891576\">8891576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Renoux C, Dell'Aniello S, Brophy JM, et al, &quot;Dopamine Agonist Use and the Risk of Heart Failure,&quot; <i>Pharmacoepidemiol Drug Saf</i>. 2012, 21(1):34-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/22109939/pubmed\" target=\"_blank\" id=\"22109939\">22109939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;RLS Medical Bulletin,&rdquo; Restless Legs Syndrome Foundation, 2005, 1-34. Available at www.rls.org . Last accessed September 11, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Safety and Efficacy of Pramipexole in Early Parkinson Disease. Parkinson Study Group,&rdquo; <i>JAMA</i>, 1997, 278(2):125-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/9214527/pubmed\" target=\"_blank\" id=\"9214527\">9214527</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shannon KM, Bennet JP Jr, and Friedman JH, &ldquo;Efficacy of Pramipexole, A Novel Dopamine Agonist, as Monotherapy in Mild to Moderate Parkinson's Disease,&rdquo; The Pramipexole Study Group, <i>Neurology</i>, 1997, 49(3):724-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silber MH, Girish M, and Izurieta R, &ldquo;Pramipexole in the Management of Restless Legs Syndrome: An Extended Study,&rdquo; <i>Sleep</i>, 2003, 26(7):819-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/14655914/pubmed\" target=\"_blank\" id=\"14655914\">14655914</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stern MB, &ldquo;Contemporary Approaches to the Pharmacotherapeutic Management of Parkinson's Disease: An Overview,&rdquo; <i>Neurology</i>, 1997, 49(1 Suppl 1):2-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/9222162/pubmed\" target=\"_blank\" id=\"9222162\">9222162</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ting RM and Force RW, &ldquo;Pramipexole for Parkinson's Disease,&rdquo; <i>J Fam Pract</i>, 1998, 46(1):19-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/9451363/pubmed\" target=\"_blank\" id=\"9451363\">9451363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watts RL, &ldquo;The Role of Dopamine Agonists in Early Parkinson's Disease,&rdquo; <i>Neurology</i>, 1997, 49(1 Suppl 1):34-48.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo; <i>Arch Neurol</i>, 2006, 63(7):969-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/16831966/pubmed\" target=\"_blank\" id=\"16831966\">16831966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winkelman JW and Johnston L, &ldquo;Augmentation and Tolerance With Long-Term Pramipexole Treatment of Restless Legs Syndrome (RLS),&rdquo; <i>Sleep Med</i>, 2004, 5(1):9-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/14725821/pubmed\" target=\"_blank\" id=\"14725821\">14725821</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15219473\"></a>Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. <i>Biol Psychiatry</i>. 2004;56(1):54-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pramipexole-drug-information/abstract-text/15219473/pubmed\" target=\"_blank\" id=\"15219473\">15219473</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9560 Version 204.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F212309\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F212310\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F212335\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F212313\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F212314\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F212315\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15028352\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F212288\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F212275\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F212291\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F212289\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744699\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F212341\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F212282\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F212294\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F212279\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299931\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F212283\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F212306\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F212297\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F212298\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F212299\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F212286\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F212278\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F212293\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F212296\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F212300\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9560|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pramipexole-patient-drug-information\" class=\"drug drug_patient\">Pramipexole: Patient drug information</a></li></ul></div></div>","javascript":null}